What Procalm (Prochlorperazine) Treats: Main Uses and Benefits

Procalm (Prochlorperazine) is generally used to help manage severe and distressing symptoms across three main therapeutic domains. It is commonly used for conditions characterized by periods of heightened symptoms and may be part of symptomatic management when functional stability becomes affected.

This medication is relevant for managing symptom clusters that may become intense or disruptive, including severe nausea and vomiting; the manifestations of schizophrenia and other psychotic disorders; vertigo; and excessive tension associated with non-psychotic anxiety. It is applied in clinical settings that involve acute or unstable symptom patterns, such as supportive care during chemotherapy or managing sickness related to surgical care. The key therapeutic benefit provides support that helps ease the overall symptom burden and contributes to improved comfort during periods of heightened symptoms.

Quick Fact: Support for Severe Nausea

Procalm is applied when appropriate for short-term symptom stabilization in situations where symptoms become temporarily overwhelming, provides supportive relief when symptoms interfere with routine activities.

Regulatory References

1. MedlinePlus Drug Information overview

Who Must Not Use Prochlorperazine (Contraindications)

Prochlorperazine is contraindicated—meaning it must not be used—in several patient populations, according to official regulatory labeling. These absolute exclusions are based on specific health conditions or sensitivities:

• Hypersensitivity: Individuals with a known allergy to Prochlorperazine or any other phenothiazine drug.
• CNS Status: Patients who are in a comatose state or have taken large amounts of Central Nervous System (CNS) depressants (e.g., alcohol, barbiturates).
• Severe Disorders: Those with severe blood dyscrasias (disorders), bone marrow depression, or established severe cardiovascular disorders.

---

️ Eligibility Limitations and Special Populations

Use is restricted or requires mandatory caution in certain groups:

Population Category	Eligibility Rule (Official Statement)
Pediatric	Contraindicated in children under 2 years of age or weighing under 20 lbs (9 kg).
Geriatric	Not approved for treating patients with dementia-related psychosis (due to increased mortality risk).
Pregnancy/Lactation	Generally not recommended. Use requires the benefit to markedly outweigh the risk, especially during the third trimester.
Comorbidities	Caution is required for patients with liver/renal impairment, glaucoma, prostatic hypertrophy, or a history of seizures or epilepsy.

Regulatory documents also state that the drug is not established for managing behavioral complications in patients with mental retardation, and it should not be used in children undergoing surgery.

Interactions with other medicines and products

Official regulatory information for Prochlorperazine focuses on two primary areas of constraint: pharmacodynamic potentiation and metabolic clearance alteration.

Contraindicated and High-Risk Combinations

Co-administration is contraindicated in comatose states or in the presence of large amounts of CNS depressants, including alcohol, barbiturates, or narcotics, due to the risk of dangerous potentiation of effects. Epinephrine (Adrenaline) must not be used to treat Prochlorperazine-induced hypotension, as this combination may cause a paradoxical further lowering of blood pressure. Additionally, the drug is restricted with QT interval prolonging drugs (e.g., Pimozide, Thioridazine) due to an increased risk of serious ventricular arrhythmias.

Pharmacodynamic and Metabolic Interactions

Prochlorperazine is metabolized in the liver, primarily via the CYP2D6 enzyme. This means co-administration with inhibitors or inducers of the CYP450 system can alter the drug's systemic exposure. Pharmacodynamic risks involve potentiation of effects when combined with anticholinergic drugs and antihypertensives, which can lead to enhanced anticholinergic symptoms or exaggerated hypotension. Concomitant use with Lithium has been associated with a risk of severe neurotoxicity, a documented adverse interaction. The drug may also lower the seizure threshold, which can diminish the efficacy of Anticonvulsants.

Prochlorperazine functions as a multi-receptor competitive antagonist primarily by disrupting chemical signaling within the central nervous system (CNS).

---

Central Dopamine D2 Receptor Blockade

The core mechanism involves the high-affinity blockade of Dopamine D2 receptors, especially in the Chemoreceptor Trigger Zone (CTZ) of the brainstem. By occupying these receptor sites, Prochlorperazine prevents the endogenous neurotransmitter dopamine from binding, thereby interrupting the signaling cascade that initiates efferent signaling toward the Vomiting Center.

---

Multi-System Receptor Modulation

The mechanistic profile is further shaped by its engagement with several other key CNS targets, including Histamine H1 receptors, alpha1-Adrenergic receptors, and Muscarinic Acetylcholine receptors. This non-selective antagonism modulates multiple neural pathways, leading to a generalized reduction in CNS excitability and altering autonomic signaling for vascular tone. This multi-system interaction contributes to the comprehensive physiological effects observed with this class of molecule.

Official Administration Guidelines for Prochlorperazine

Prochlorperazine is administered across multiple routes, allowing for flexibility based on the clinical setting and patient needs. The official labeled routes include oral (swallowed tablets), buccal (cheek absorption), rectal (suppository), and parenteral (Intramuscular or Intravenous injection).

Oral forms are typically dosed in a divided manner, administered three or four times a day. The maximum daily dose for severe nausea and vomiting is 40 mg, while for non-psychotic anxiety, the maximum is restricted to 20 mg daily. Schizophrenia maintenance doses can be significantly higher, up to 150 mg daily. The official use for non-psychotic anxiety is time-limited and must not exceed 12 weeks.

Administration Technique and Timing

Administration Type	Key Labeled Instruction
Oral Tablets	May be taken with or without food.
Buccal Tablets	Placed high along the upper gum, must be allowed to dissolve, and must not be chewed or swallowed.
Intravenous (IV) Use	Must be given as a slow injection or infusion at a rate not exceeding 5 mg per minute.
Long-Term Discontinuation	The dose must be gradually reduced if taken over a prolonged period.

Population-Specific Instructions

Dosage adjustments are required for certain populations. A lower initial dose is recommended for older adults. For pediatric patients, use is not recommended in children under two years of age or weighing less than 9 kg (20 lbs), and dosing is based on the child’s body weight where approved.

Research Evidence / Overview of Studies

---

Focus of Pre-Clinical Research

Pre-clinical research suggests the compound may act by activating specific pathways in the central nervous system. This activation is thought to be related to the transmission of pain signals. Pre-clinical investigations focus on the role of neurotransmitter reuptake, which studies suggest may be relevant to the regulation of mood.

---

Clinical Trials and Findings

The compound has been evaluated in studies for managing certain types of chronic pain. Research explored the time to onset of changes in pain perception following administration. The primary endpoint in these trials was to evaluate whether there was a reduction in the severity of pain over a six-week period.

• Trial 1 (Duration: 12 weeks, n=500): This study examined the compound's use in individuals with neuropathic pain. Findings were mixed, with some participants reporting changes, while others did not.
• Trial 2 (Duration: 6 months, n=850): This larger research examined whether the compound was associated with a prolonged period of reduction in daily pain interference. Evidence remains limited regarding long-term outcomes, and continued research is needed.

---

Safety and Tolerance

• Side Effects: The 100 mg daily level was the most frequently studied dose. The most common side effects reported across various trials included dizziness, nausea, and fatigue. These effects were generally reported as transient and low in severity.
• Special Populations: Study participants were adults without major existing conditions. Research has noted that participants with severe kidney issues were often excluded from trials. It is not yet clear whether the safety profile is different in pediatric or elderly populations.

---

Combination Therapy

A combination evaluated for use with certain non-steroidal anti-inflammatory drugs (NSAIDs) was studied. The research explored the potential for an additive effect on pain measures. Results suggested a potential trend toward improved outcomes in a subset of patients, but further research is required to confirm these preliminary findings.

Key Studies & References

1. Prochlorperazine: Uses, Interactions, Mechanism of Action | DrugBank Online
2. Repetitive intravenous prochlorperazine treatment of patients with refractory chronic daily headache

Common questions about Procalm (Prochlorperazine) (FAQ)

---

Q: Is Procalm (Prochlorperazine) the same as Compro?

Prochlorperazine is the active ingredient in the medicine. While Procalm is a trade name for this ingredient, another well-known trade name referenced in regulatory documents is Compazine. Official product information confirms that both brand names contain the active substance Prochlorperazine.

---

Q: How quickly does Procalm (Prochlorperazine) start to work for nausea?

The official product information specifies the time to onset of action for different administration routes. Following an intramuscular injection, the effects of Prochlorperazine can begin relatively quickly, often starting within ten to twenty minutes.

---

Q: How long do the effects of Procalm (Prochlorperazine) last?

For the treatment of nausea and vomiting, the therapeutic effects of the medicine are generally time-limited. Following an intramuscular injection, the duration of action is typically reported in official prescribing information as lasting for three to four hours.

---

Q: Is Procalm (Prochlorperazine) addictive?

According to regulatory sources in the United States, Prochlorperazine is not currently listed as a controlled substance by the Drug Enforcement Administration (DEA). This means it is not classified in the categories of drugs that have a recognized potential for abuse or dependency.

---

Q: Is Procalm (Prochlorperazine) safe to use while breastfeeding?

Official product information from international regulatory authorities indicates that use during breastfeeding is generally not recommended or advised against. This cautionary approach is taken because the medicine may pass into breast milk, and its effects on the nursing infant are not fully established.

---

Q: Is Procalm (Prochlorperazine) a type of antihistamine?

Prochlorperazine is primarily classified as an antiemetic (for sickness) and an antipsychotic. While it acts by blocking several chemical signals, including some that affect histamine receptors, this activity is secondary to its main function as a dopamine blocker in the brain.

---

Q: Does Procalm (Prochlorperazine) help with chronic dizziness or vertigo?

International regulatory-backed sources indicate that the medicine may be authorized for use in managing symptoms of vertigo (a severe feeling of spinning or dizziness). Its official scope can also include certain conditions that affect balance, such as Ménière's disease.

---

Q: Can Procalm (Prochlorperazine) be used for motion sickness?

Official product information in some countries describes the use of Prochlorperazine for the treatment of motion sickness. It is employed to help control the severe feelings of nausea and vomiting often associated with travel.

---

Q: What is the evidence for using Procalm (Prochlorperazine) to treat a migraine headache?

Official regulatory documents in certain regions include the use of Prochlorperazine for the severe feelings of sickness and vomiting associated with migraine headaches. The anti-nausea effect is often leveraged in these situations, according to prescribing information.

---

Q: Can Procalm (Prochlorperazine) affect my ability to drive or operate machinery?

Official safety warnings indicate that the drug may impair the abilities required for potentially hazardous tasks, such as driving a car or operating hazardous machinery. This is due to the risk of drowsiness and sedation that is associated with the medicine.

---

Q: What does the term 'phenothiazine' mean in relation to Procalm (Prochlorperazine)?

Prochlorperazine belongs to the chemical class known as phenothiazines. This class refers to a group of medicines that primarily function as antipsychotic drugs, mainly by blocking dopamine receptors in the central nervous system. This chemical structure is related to the drug’s varied effects.

---

Q: Is there a maximum time that Procalm (Prochlorperazine) is generally used?

Official labeling documents place a clear limit on the duration of use for certain conditions. When the drug is used for non-psychotic anxiety, it should not be administered for longer than 12 weeks. This restriction exists due to the potential risk of developing irreversible involuntary movement disorders.

---

Q: Can Procalm (Prochlorperazine) be taken with antacids?

Official warnings suggest caution regarding concurrent use with certain antacids, specifically those containing magnesium hydroxide. Caution is advised because this combination may potentially be associated with an increased risk of an irregular heart rhythm in some individuals.

---

Q: What types of allergic reactions are possible with Procalm (Prochlorperazine)?

As with many medications, official safety information indicates a risk of severe allergic reactions with Prochlorperazine. Symptoms highlighted in regulatory-sourced information may include difficulty breathing due to swelling of the mouth or throat, severe itching, and the sudden appearance of a significant skin rash.

---

Q: Does Procalm (Prochlorperazine) interact with herbal supplements like St. John's Wort?

Official safety advice from regulatory bodies mentions the need for caution regarding certain herbal products. Regulatory information indicates that the use of herbal supplements such as St. John's Wort should be discussed with a healthcare provider.

---

Q: Is Procalm (Prochlorperazine) used in cancer patients for chemotherapy-induced nausea?

Official drug labels and clinical guidelines recognize the role of Prochlorperazine for managing nausea and vomiting in certain contexts. It is used in regimens associated with low emetogenic risk chemotherapy and for breakthrough nausea when other treatments are insufficient.

---

Q: Why is there a warning about Procalm (Prochlorperazine) and liver problems?

Caution is advised for people who have a history of liver disease or liver impairment. This is because the drug is processed in the liver, and impairment of this organ could potentially lead to a higher amount of the medicine remaining in the body, which could increase the risk of adverse effects.

---

Q: Does Procalm (Prochlorperazine) interact with medications for sleep?

Regulatory warnings are in place regarding the combination of Prochlorperazine with medicines that cause drowsiness or sedation, which includes most medications used for sleep. Taking them together can significantly potentiate (increase) the effect of the central nervous system depression.

---

Q: Is Procalm (Prochlorperazine) generally suitable for use in teenagers?

Official product information for this drug includes weight-based dosing guidance for children, and use is generally avoided in the youngest age groups. However, specific, distinct suitability guidance for the adolescent or teenage population is generally not provided separately from the adult or younger pediatric guidance.

---

Q: Does Procalm (Prochlorperazine) cause constipation or diarrhea?

Official adverse reaction lists indicate that constipation is a common gastrointestinal side effect associated with this medicine. In contrast, diarrhea is not commonly listed in regulatory documents as a known adverse event.

How to Store and Dispose of Procalm (Prochlorperazine)

Official regulatory documents define specific conditions to maintain the stability of Procalm (prochlorperazine). Tablets must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The medication must be protected from light and stored in a tight, light-resistant container.

Required Storage and Handling

• Temperature: Store at Controlled Room Temperature.
• Protection: Protect from light; do not freeze.
• Safety: The product must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Prochlorperazine must be disposed of according to local regulations. It must not be discarded via wastewater or routine household waste.